

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Ascletis Pharma Inc.**

**歌禮製藥有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1672)**

**ANNOUNCEMENT  
INSIDE INFORMATION**

**PROGRESS OF THE SMALL SAMPLE  
CLINICAL TRIAL OF GANOVO® (DANOPRE VIR) AND RITONAVIR  
COMBINATION THERAPY ON NOVEL CORONAVIRUS PNEUMONIA**

This announcement is made by Ascletis Pharma Inc. (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement dated February 27, 2020, in relation to the small sample clinical trial (NCT04291729) of oral Ganovo® and Ritonavir combination therapy on the Novel Coronavirus Pneumonia, led by Dr. Hongyi CHEN (陳宏義), the director of the Ninth Hospital of Nanchang (南昌市第九醫院), which has obtained approval from the ethics committee of the Ninth Hospital of Nanchang on February 16, 2020.

One of the treatment groups in this study is the group receiving oral Ganovo® and Ritonavir combination therapy, in which 10 Novel Coronavirus Pneumonia patients were planned to be enrolled, and 11 patients actually enrolled. As of the date of this announcement, all 11 patients receiving oral Ganovo® and Ritonavir combination therapy have been discharged as they are satisfied with the discharge standards under the “Diagnosis and Treatment Program for Novel Coronavirus Infection (Trial Version 6)” (《新型冠狀病毒肺炎診療方案(試行第六版)》) issued by the National Health Commission of the People’s Republic of China.

Ganovo® (Danoprevir), an oral Hepatitis C virus (HCV) protease inhibitor, was approved by the National Medical Products Administration for market launch in June 2018, which is used to treat chronic Hepatitis C and a commercialized product of the Company.

**Cautionary Statement required by Rule 18A.05 of the Listing Rules:** We cannot guarantee that we will obtain approval for, or ultimately market Ritonavir successfully.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Ascletris Pharma Inc.**  
歌禮製藥有限公司  
**Jinzi Jason WU**  
*Chairman*

Hangzhou, the People's Republic of China,  
March 10, 2020

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; Dr. Ru Rong JI, Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.*